GeNeuro Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Public

  • Employees
  • 19

Employees

  • Stock Symbol
  • GNRO

Stock Symbol

  • Share Price
  • $2.07
  • (As of Friday Closing)

GeNeuro General Information

Description

GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).

Contact Information

Website
www.geneuro.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Stock Exchange
PAR
Corporate Office
  • 3, Chemin du Pré-Fleuri
  • Plan-les-Ouates
  • 1228 Geneva
  • Switzerland
+41 022 000 00 00

GeNeuro Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GeNeuro Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.07 $2.15 $1.00 - $2.28 $61.1M 29.6M 9.3K -$0.64

GeNeuro Financials Summary

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 35,875 35,875 33,408 87,204
Revenue 0 0 0 0
EBITDA (15,728) (15,728) (12,529) (7,708)
Net Income (15,968) (15,968) (12,827) (8,061)
Total Assets 7,032 7,032 12,301 14,198
Total Debt 14,776 14,776 7,486 4,246
Public Fundamental Data provided by Morningstar, Inc. disclaimer

GeNeuro Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore GeNeuro‘s full profile, request access.

Request a free trial

GeNeuro Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving th
Drug Discovery
Geneva, Switzerland
19 As of 2023
000.00
000000000 000.00

000000

r incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nos
0000000000000
Gothenburg, Sweden
0 As of 0000
0000000000

000000

por incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis n
0000000000000
Zug, Switzerland
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

GeNeuro Competitors (52)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alzinova Corporation Gothenburg, Sweden 0 0000000000
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland 000 00000 000000000 00000
Bicycle Therapeutics Formerly VC-backed Cambridge, United Kingdom 000 00.000 000000000 00.000
Senti Bio Formerly VC-backed South San Francisco, CA 00 00000 000000000000 00000
Quince Therapeutics Formerly VC-backed South San Francisco, CA 00 00000 000000&0
You’re viewing 5 of 52 competitors. Get the full list »

GeNeuro Patents

GeNeuro Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3916015-A1 Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases Inactive 28-May-2020 00000000000 0
CA-3185024-A1 Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases Pending 28-May-2020 00000000000
EP-4157871-A1 Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases Pending 28-May-2020 00000000000
AU-2021281054-A1 Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases Pending 28-May-2020 00000000000
US-20200308258-A1 Anti-herv-k envelope antibody and uses thereof Active 20-Jan-2017 C07K16/1036
To view GeNeuro’s complete patent history, request access »

GeNeuro Executive Team (9)

Name Title Board Seat Contact Info
Miguel Payró Chief Financial Officer
Alois Lang Ph.D Chief Development Officer
Herve Perron Ph.D Co-Founder & Chief Scientific Officer
Anke Post Chief Medical Officer
Jesús Martin-Garcia Chief Executive Officer & Founder
You’re viewing 5 of 9 executive team members. Get the full list »

GeNeuro Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GeNeuro Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore GeNeuro‘s full profile, request access.

Request a free trial

GeNeuro ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view GeNeuro’s complete esg history, request access »

GeNeuro FAQs

  • When was GeNeuro founded?

    GeNeuro was founded in 2006.

  • Who is the founder of GeNeuro?

    Herve Perron Ph.D and Jesús Martin-Garcia are the founders of GeNeuro.

  • Who is the CEO of GeNeuro?

    Jesús Martin-Garcia is the CEO of GeNeuro.

  • Where is GeNeuro headquartered?

    GeNeuro is headquartered in Geneva, Switzerland.

  • What is the size of GeNeuro?

    GeNeuro has 19 total employees.

  • What industry is GeNeuro in?

    GeNeuro’s primary industry is Drug Discovery.

  • Is GeNeuro a private or public company?

    GeNeuro is a Public company.

  • What is GeNeuro’s stock symbol?

    The ticker symbol for GeNeuro is GNRO.

  • What is the current stock price of GeNeuro?

    As of 24-May-2024 the stock price of GeNeuro is $2.07.

  • What is the current market cap of GeNeuro?

    The current market capitalization of GeNeuro is $61.1M.

  • Who are GeNeuro’s competitors?

    Alzinova, CRISPR Therapeutics, Bicycle Therapeutics, Senti Bio, and Quince Therapeutics are some of the 52 competitors of GeNeuro.

  • What is GeNeuro’s annual earnings per share (EPS)?

    GeNeuro’s EPS for 12 months was -$0.64.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »